Skip to content
value.today
Editas Medicine, Inc. logo

Editas Medicine, Inc.

EDIT
$363 Mmarket cap on Oct 19, 2026-53.4% since Jan 2024
1D
-4.1%
Compare
World rank
#13,968
Revenue
$41 M
For year ending December-2025
Net income
$-160 M
-395.0% margin
SEC filing
Employees
264
As on 2021
value.today research

Editas Medicine, Inc. in brief

Editas Medicine, Inc. is a listed company in the Biotechnology industry, based in Cambridge, Massachusetts, USA. It was founded in 2013. Its market value was $363 M on 19 October 2026, which makes it the 13,968th largest listed company in the world and the 2,743rd largest in the USA on this site. In the year to December 2025 it had sales of $41 M and a net loss of $160 M. It employs about 264 people and Gilmore Neil O'Neill is its chief executive. Its largest business segments by sales in 2025 were Reportable (100%). Its shares trade under the symbol EDIT (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Editas Medicine, Inc.

Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Editas Medicine, Inc. timeline

5 events, 2013–2023
  1. 2013
  2. 🏁
    Founded
  3. 2015
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2016
  6. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 3 February 2016; shares registered for exchange trading on 29 January 2016.
  7. 2018
  8. •
    Legal Entity Identifier issued
    LEI 5299000AON4Q9NT2JE42 registered.
  9. 2023
  10. 💰
    Record revenue of $78 million
    FY2023, the highest of the 7 years on record.

Events of Editas Medicine, Inc. from Wikidata, SEC EDGAR, the GLEIF LEI register and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$1.2 B$2.4 B$3.5 B$4.7 B2020202120222023202420252026

World rank over time

▼ down 7,904 places since 2020
2020-01-01: #6106#6,10620202021-01-01: #3276#3,27620212022-01-07: #6883#6,88320222022-12-25: #11186#11,18620222023-07-30: #10631#10,63120232024-01-05: #9927#9,92720242026-03-08: #9029#9,02920262026-08-01: #12817#12,81720262026-10-14: #13877#13,87720262026-10-19: #14010#14,0102026

Rank in USA: #1,771 (Jan 2020) · #1,084 (Jan 2021) · #2,001 (Jan 2022) · #2,429 (Dec 2022) · #2,390 (Jul 2023) · #2,209 (Jan 2024) · #1,716 (Mar 2026) · #2,616 (Aug 2026) · #2,710 (Oct 2026) · #2,747 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
7.3×
Price / book
13.3×
Free cash flow yield
-45.7%
Net margin (TTM)
-144.9%
Operating margin
-394.9%
Return on equity
-264.6%
Liabilities / assets
85.4%
Net debt
$-93M
Revenue growth
+25.4%
R&D / revenue
222.0%
Revenue per employee
$153 K
Profit per employee
$-606 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $32M, net income $-110M$32MFY18Fiscal year ending Dec 2019: revenue $21M, net income $-134M$21MFY19Fiscal year ending Dec 2020: revenue —, net income $-116M—FY20Fiscal year ending Dec 2021: revenue $26M, net income $-193M$26MFY21Fiscal year ending Dec 2022: revenue $20M, net income $-220M$20MFY22Fiscal year ending Dec 2023: revenue $78M, net income $-153M$78MFY23Fiscal year ending Dec 2024: revenue $32M, net income $-237M$32MFY24Fiscal year ending Dec 2025: revenue $41M, net income $-160M$41MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$41M+25.4%$-160M$-160M-395.0%
Dec 2024$32M-58.6%$-251M$-237M-733.8%
Dec 2023$78M+296.3%$-169M$-153M-196.1%
Dec 2022$20M-22.8%$-226M$-220M-1118.4%
Dec 2021$26M—$-193M$-193M-753.7%
Dec 2020——$-135M$-116M—
Dec 2019$21M-35.7%$-141M$-134M-651.5%
Dec 2018$32M—$-114M$-110M-344.2%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-165M$1M$-166M$-1.80—
Dec 2024$-210M$9M$-219M$-2.88—
Dec 2023$-132M$5M$-137M$-2.02—
Dec 2022$-177M$4M$-181M$-3.21—
Dec 2021$-164M$8M$-172M$-2.85—
Dec 2020$-180M$7M$-187M$-1.98—
Dec 2019$-41M$6M$-47M$-2.68—
Dec 2018$-46M$5M$-50M$-2.33—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$50M
Net income, trailing 12 months
$-72M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $31M, net income $-45M$31MDec ’24Three months to Mar 2025: revenue $5M, net income $-76M$5MMar ’25Three months to Jun 2025: revenue $4M, net income $-53M$4MJun ’25Three months to Sep 2025: revenue $8M, net income $-25M$8MSep ’25Three months to Dec 2025 (from the annual report): revenue $25M, net income $-6M$25MDec ’25Three months to Mar 2026: revenue $3M, net income $-25M$3MMar ’26Three months to Jun 2026: revenue $12M, net income $-18M$12MJun ’26Three months to Sep 2026: revenue $10M, net income $-23M$10MSep ’26

Latest quarter to Sep 2026: revenue $10M (+37.4% on a year earlier), net income $-23M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Editas Medicine, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$41 M
Operating income
$-160 M
Net income
$-160 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$187 M
Total liabilities
$159 M
Total equity
$27 M

As of December-2025

Top 100 institutional investors in Editas Medicine, Inc.#

As of Sep 30, 2026
220 institutions held 139.5 M shares (about 90.3% of the shares outstanding) on Sep 30, 2026. The ten largest hold 52.8%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Editas Medicine, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1BlackRock, Inc.14,402,109+3,812,119 (+36.00%)9.33%$37 MNov 13, 2026
2TCG Crossover Management, LLC11,111,1110 (0.00%)7.20%$29 MNov 16, 2026
3Ra Capital Management, L.P.8,889,0000 (0.00%)5.76%$23 MNov 16, 2026
4Commodore Capital LP8,889,0000 (0.00%)5.76%$23 MNov 16, 2026
5ADAR1 Capital Management, LLC8,889,0000 (0.00%)5.76%$23 MNov 16, 2026
6Paradigm Biocapital Advisors LP7,575,140+1,988,515 (+35.59%)4.91%$19 MNov 16, 2026
7State Street Corp7,038,580+4,846,777 (+221.13%)4.56%$18 MNov 12, 2026
8Vanguard Capital Management LLC6,073,405-67,931 (-1.11%)3.94%$16 MNov 13, 2026
9Vanguard Portfolio Management LLC4,681,324+1,082,985 (+30.10%)3.03%$12 MNov 13, 2026
10Geode Capital Management, LLC3,888,523+1,319,451 (+51.36%)2.52%$10 MNov 6, 2026
11Woodline Partners LP3,555,4970 (0.00%)2.30%$9 MNov 16, 2026
12Vivo Capital, LLC3,555,2500 (0.00%)2.30%$9 MNov 13, 2026
13Opaleye Management Inc.3,486,452-375,478 (-9.72%)2.26%$9 MNov 16, 2026
14Goldman Sachs Group Inc3,245,032+630,996 (+24.14%)2.10%$8 MNov 16, 2026
15D. E. Shaw & Co., Inc.3,190,146+1,289,144 (+67.81%)2.07%$8 MNov 16, 2026
16GordonMD Global Investments LP3,127,0000 (0.00%)2.03%$8 MNov 16, 2026
17Marshall Wace, LLP3,024,503+987,216 (+48.46%)1.96%$8 MNov 13, 2026
18Renaissance Technologies LLC2,497,638+28,719 (+1.16%)1.62%$6 MNov 12, 2026
19Logos Global Management LP2,222,0000 (0.00%)1.44%$6 MNov 16, 2026
20Seven Fleet Capital Management LP1,915,871+585,371 (+44.00%)1.24%$5 MNov 16, 2026
21Jpmorgan Chase & Co1,866,640+4,146 (+0.22%)1.21%$5 MNov 12, 2026
22UBS Group AG1,427,276+676,513 (+90.11%)0.92%$4 MNov 10, 2026
23Two Sigma Investments, LP1,320,169-12,807 (-0.96%)0.86%$3 MNov 16, 2026
24Raymond James Financial Inc1,317,272-1,675 (-0.13%)0.85%$3 MNov 12, 2026
25Kennedy Capital Management LLC1,302,373+270,240 (+26.18%)0.84%$3 MNov 13, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Editas Medicine, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Charles Schwab Investment Management Inc1,241,002+372,970 (+42.97%)0.80%$3 MNov 16, 2026
27Northern Trust Corp1,193,623+373,930 (+45.62%)0.77%$3 MNov 16, 2026
28Ameriprise Financial Inc1,129,721New0.73%$3 MNov 16, 2026
29HighVista Strategies LLC1,107,128New0.72%$3 MNov 13, 2026
30Vanguard Fiduciary Trust Co984,633+241,683 (+32.53%)0.64%$3 MNov 13, 2026
31AQR Capital Management LLC981,513-590,729 (-37.57%)0.64%$3 MNov 16, 2026
32Nantahala Capital Management, LLC852,700-852,700 (-50.00%)0.55%$2 MNov 13, 2026
33Acadian Asset Management LLC639,634-399,367 (-38.44%)0.41%$2 MNov 9, 2026
34Los Angeles Capital Management LLC602,946+331,760 (+122.34%)0.39%$2 MNov 12, 2026
35Nuveen, LLC550,797+29,584 (+5.68%)0.36%$1 MNov 10, 2026
36Bank Of America Corp /de/521,374+289,547 (+124.90%)0.34%$1 MNov 16, 2026
37Point72 Asset Management, L.P.512,506+387,272 (+309.24%)0.33%$1 MNov 16, 2026
38Barclays PLC510,903+361,639 (+242.28%)0.33%$1 MNov 6, 2026
39Eversept Partners, LP456,923-1,886 (-0.41%)0.30%$1 MNov 16, 2026
40Casdin Capital, LLC445,0000 (0.00%)0.29%$1 MNov 16, 2026
41Morgan Stanley436,277+94,112 (+27.50%)0.28%$1 MNov 13, 2026
42Bank of New York Mellon Corp391,021+128,396 (+48.89%)0.25%$1 MNov 5, 2026
43Wellington Management Group LLP365,035+55,640 (+17.98%)0.24%$1 MNov 16, 2026
44Susquehanna Portfolio Strategies, LLC361,685-115,414 (-24.19%)0.23%$1 MNov 16, 2026
45Invesco Ltd.279,477+67,597 (+31.90%)0.18%$1 MNov 12, 2026
46MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.260,038+108,632 (+71.75%)0.17%$1 MNov 16, 2026
47Susquehanna International Group, LLP253,937+161,092 (+173.51%)0.16%$1 MNov 16, 2026
48LPL Financial LLC240,754+9,639 (+4.17%)0.16%$1 MNov 6, 2026
49Quadrature Capital Ltd236,538New0.15%$1 MNov 13, 2026
50Citadel Advisors LLC234,312+21,551 (+10.13%)0.15%$1 MNov 16, 2026
51Gsa Capital Partners LLP231,772-135,375 (-36.87%)0.15%$1 MNov 16, 2026
52Erste Asset Management GmbH230,0000 (0.00%)0.15%$1 MNov 12, 2026
53Millennium Management LLC211,484-287,513 (-57.62%)0.14%$1 MNov 16, 2026
54Peak6 LLC197,144-218,297 (-52.55%)0.13%$1 MNov 13, 2026
55Rafferty Asset Management, LLC183,590New0.12%$0 MNov 13, 2026
56DAFNA Capital Management LLC180,470+10,000 (+5.87%)0.12%$0 MNov 16, 2026
57Russell Investments Group, Ltd.177,786+27,922 (+18.63%)0.12%$0 MNov 6, 2026
58Squarepoint Ops LLC177,198New0.11%$0 MNov 9, 2026
59Price T Rowe Associates Inc /MD/172,865+53,436 (+44.74%)0.11%$0 MNov 16, 2026
60Cambridge Investment Research Advisors, Inc.161,244-162,512 (-50.20%)0.10%$0 MNov 2, 2026
61Connor, Clark & Lunn Investment Management Ltd.158,357New0.10%$0 MNov 10, 2026
62Alliancebernstein L.P.156,980-30,950 (-16.47%)0.10%$0 MNov 16, 2026
63XTX Topco Ltd146,283+122,315 (+510.33%)0.09%$0 MNov 16, 2026
64Rhumbline Advisers137,863+20,446 (+17.41%)0.09%$0 MNov 10, 2026
65Deutsche Bank AG\134,632+35,267 (+35.49%)0.09%$0 MNov 6, 2026
66Ieq Capital, LLC126,083-91,702 (-42.11%)0.08%$0 MNov 10, 2026
67Bridgeway Capital Management, LLC123,882-2,118 (-1.68%)0.08%$0 MNov 16, 2026
68Empowered Funds, LLC123,882New0.08%$0 MNov 13, 2026
69Mariner, LLC119,606-49,685 (-29.35%)0.08%$0 MNov 12, 2026
70FMR LLC114,322+3,124 (+2.81%)0.07%$0 MNov 10, 2026
71Canada Pension Plan Investment Board109,500+67,100 (+158.25%)0.07%$0 MNov 16, 2026
72CANADA LIFE ASSURANCE Co106,586+27,984 (+35.60%)0.07%$0 MNov 13, 2026
73MetLife Investment Management, LLC90,085+33,869 (+60.25%)0.06%$0 MNov 16, 2026
74American Century Companies Inc84,482-8,114 (-8.76%)0.05%$0 MNov 12, 2026
75Citigroup Inc80,886+18,922 (+30.54%)0.05%$0 MNov 4, 2026
76Panagora Asset Management Inc77,969New0.05%$0 MNov 12, 2026
77Wells Fargo & Company/mn73,325-47,428 (-39.28%)0.05%$0 MNov 16, 2026
78Graham Capital Management, L.P.73,290+31,818 (+76.72%)0.05%$0 MNov 16, 2026
79SEI Investments Co73,084+4,816 (+7.05%)0.05%$0 MNov 10, 2026
80BNP Paribas Financial Markets72,378+50,393 (+229.22%)0.05%$0 MNov 12, 2026
81Stifel Financial Corp72,338-2,444 (-3.27%)0.05%$0 MNov 12, 2026
82Prudential Financial Inc70,750+52,010 (+277.53%)0.05%$0 MNov 16, 2026
83Joel Isaacson & Co., LLC68,1440 (0.00%)0.04%$0 MNov 5, 2026
84Qube Research & Technologies Ltd65,959New0.04%$0 MNov 13, 2026
85Profund Advisors LLC65,291New0.04%$0 MOct 29, 2026
86China Universal Asset Management Co., Ltd.64,022+19,598 (+44.12%)0.04%$0 MOct 28, 2026
87Group One Trading LLC58,831+8,482 (+16.85%)0.04%$0 MNov 10, 2026
88MML Investors Services, LLC57,820+5,732 (+11.00%)0.04%$0 MNov 13, 2026
89Vanguard Global Advisers, LLC54,714+11,851 (+27.65%)0.04%$0 MNov 13, 2026
90New York State Common Retirement Fund54,294+49,900 (+1135.64%)0.04%$0 MNov 17, 2026
91Creative Planning49,412+3,840 (+8.43%)0.03%$0 MNov 2, 2026
92Turner Financial Group, Inc.44,956New0.03%$0 MNov 9, 2026
93Police & Firemen's Retirement System of New Jersey43,559+9,686 (+28.60%)0.03%$0 MNov 9, 2026
94Brevan Howard Capital Management LP43,415+29,056 (+202.35%)0.03%$0 MNov 16, 2026
95Osaic Holdings, Inc.43,386-26,738 (-38.13%)0.03%$0 MNov 12, 2026
96EntryPoint Capital, LLC41,544+14,600 (+54.19%)0.03%$0 MNov 13, 2026
97Manufacturers Life Insurance Company, The41,474+14,209 (+52.11%)0.03%$0 MNov 13, 2026
98Vanguard Personalized Indexing Management, LLC40,850+2,545 (+6.64%)0.03%$0 MNov 16, 2026
99Quinn Opportunity Partners LLC40,0000 (0.00%)0.03%$0 MNov 10, 2026
100Wealth Enhancement Advisory Services, LLC39,243-52,851 (-57.39%)0.03%$0 MOct 13, 2026

All 220 institutional investors, with who bought and sold →

Mutual funds holding Editas Medicine, Inc.#

117 funds hold shares worth $67 M (about 13.6% of the company). Since their previous reports 55 added shares and 31 sold, buying $6 M net.
Mutual funds holding Editas Medicine, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.4.89 M$16 M3.2%<0.01%+62%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors2.64 M$9 M1.7%0.01%+11%Jun 30, 2026
🇺🇸 Vanguard Strategic Equity FundThe Vanguard Group, Inc.2.03 M$7 M1.3%0.05%+8.5%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.1.10 M$4 M0.71%<0.01%+2.2%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC1.09 M$3 M0.71%<0.01%+12%Jul 31, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors844,017$3 M0.55%0.02%newJun 30, 2026
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors687,467$2 M0.45%0.02%−6.0%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC509,394$2 M0.33%<0.01%+53%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.505,306$2 M0.33%<0.01%+13%May 31, 2026
🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc.476,309$2 M0.31%<0.01%−1.6%May 31, 2026
🇺🇸 Vanguard Strategic Small-Cap Equity FundThe Vanguard Group, Inc.415,301$1 M0.27%0.04%no changeJun 30, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors336,592$1 M0.22%0.07%+36%Jun 30, 2026
🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc.291,435$1 M0.19%<0.01%+7.8%May 31, 2026
🇺🇸 JPMorgan Small Cap Value FundJ.P. Morgan Investment Management Inc.278,861$1 M0.18%0.07%−5.7%Jun 30, 2026
🇺🇸 JPMorgan U.S. Small Company FundJ.P. Morgan Investment Management Inc.278,830$1 M0.18%0.08%−6.7%Jun 30, 2026
🇺🇸 BlackRock Advantage Small Cap Growth FundBlackRock Funds269,751$1 M0.17%0.10%+43%Jun 30, 2026
🇺🇸 BlackRock Advantage Small Cap Core FundBlackRock Advisors, LLC231,010$1 M0.15%0.02%newMay 29, 2026
🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC238,520$1 M0.15%<0.01%newJun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.243,722$1 M0.16%<0.01%+13%Jul 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC173,990$1 M0.11%<0.01%no changeMay 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC185,216$1 M0.12%0.01%+30%Jun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC146,497$1 M0.09%<0.01%+5.2%May 31, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC126,000$0 M0.08%0.28%no changeJun 30, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors121,315$0 M0.08%<0.01%−86%Jun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC111,550$0 M0.07%0.02%+33%Jun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC133,489$0 M0.09%<0.01%+20%Jul 31, 2026
🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc.96,350$0 M0.06%<0.01%+1.5%May 31, 2026
🇺🇸 Multi-Manager Small Cap Equity Strategies FundColumbia Funds Series Trust I95,393$0 M0.06%0.03%−38%May 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC101,390$0 M0.07%<0.01%no changeJun 30, 2026
🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC89,916$0 M0.06%<0.01%+14%May 31, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC119,007$0 M0.08%0.01%+62%Jul 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.83,985$0 M0.05%<0.01%+50%Jun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC83,965$0 M0.05%0.02%newJun 30, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.75,517$0 M0.05%0.02%+14%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC66,134$0 M0.04%<0.01%no changeMay 31, 2026
🇺🇸 JPMorgan Small Cap Value PortfolioBrighthouse Investment Advisers, LLC68,596$0 M0.04%0.07%−14%Jun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.66,901$0 M0.04%<0.01%+26%Jun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC62,920$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 LVIP JPMorgan Small Cap Core FundLincoln Financial Investments Corporation62,222$0 M0.04%0.08%−5.3%Jun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation61,938$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC77,314$0 M0.05%<0.01%no changeJul 31, 2026
🇺🇸 Small Cap Value FundThe Variable Annuity Life Insurance Company56,803$0 M0.04%0.08%newMay 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.55,042$0 M0.04%<0.01%+74%Jun 30, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors53,398$0 M0.03%<0.01%+60%Jun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.64,120$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.46,207$0 M0.03%<0.01%−8.9%Jun 30, 2026
🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc.43,300$0 M0.03%0.01%no changeJun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC53,033$0 M0.03%<0.01%−4.5%Jul 31, 2026
🇺🇸 AQR Small Cap Multi-Style FundAQR CAPITAL MANAGEMENT, LLC41,896$0 M0.03%0.04%newJun 30, 2026
🇺🇸 Vy Jpmorgan Small Cap Core Equity PortfolioVoya Investments, LLC40,956$0 M0.03%0.04%−5.0%Jun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company37,372$0 M0.02%<0.01%+7.3%May 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC39,850$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 Siit Small Cap II FundSEI INVESTMENTS MANAGEMENT CORPORATION37,088$0 M0.02%0.05%no changeMay 31, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC47,823$0 M0.03%<0.01%+12%Jul 31, 2026
🇺🇸 AVIP BlackRock Advantage Small Cap Growth PortfolioCONSTELLATION INVESTMENTS INC37,572$0 M0.02%0.09%newJun 30, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC44,179$0 M0.03%0.01%+59%Jul 31, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust32,379$0 M0.02%<0.01%newMay 31, 2026
🇺🇸 Siit Small Cap FundSEI INVESTMENTS MANAGEMENT CORPORATION31,251$0 M0.02%0.06%no changeMay 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.32,539$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 AQR Small Cap Momentum Style FundAQR CAPITAL MANAGEMENT, LLC41,896$0 M0.03%0.06%—Mar 31, 2026
🇺🇸 BlackRock Advantage SMID Cap Fund, Inc.BlackRock Advisors, LLC31,081$0 M0.02%0.01%no changeJun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC30,771$0 M0.02%<0.01%−4.3%Jun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC27,860$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC34,800$0 M0.02%<0.01%+0.7%Jul 31, 2026
🇺🇸 SIMT Small Cap FundSEI Institutional Managed Trust25,247$0 M0.02%0.02%no changeJun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC24,946$0 M0.02%<0.01%−9.0%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS22,592$0 M0.01%0.01%+28%Jun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC22,374$0 M0.01%0.03%+26%Jun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC21,319$0 M0.01%0.01%+17%Jun 30, 2026
🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors18,768$0 M0.01%<0.01%−0.8%Jun 30, 2026
🇺🇸 Goldman Sachs Small Cap Growth Insights FundGoldman Sachs Asset Management, L.P.23,432$0 M0.02%0.02%newJul 31, 2026
🇺🇸 BlackRock Advantage SMID Cap V.I. FundBlackRock Advisors, LLC17,575$0 M0.01%0.03%no changeJun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION15,400$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.15,662$0 M0.01%0.01%+19%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.15,263$0 M<0.01%0.01%+30%Jun 30, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC14,985$0 M<0.01%<0.01%−88%Jun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC14,825$0 M<0.01%0.01%+44%Jun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.17,642$0 M0.01%<0.01%+58%Jul 31, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC13,394$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC13,312$0 M<0.01%0.01%+33%Jun 30, 2026
🇺🇸 SA Multi-Managed Small Cap PortfolioSunAmerica Asset Management, LLC13,144$0 M<0.01%0.03%−9.1%Jun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC14,750$0 M<0.01%<0.01%+0.4%Jul 31, 2026
🇺🇸 EQ/Common Stock Index PortfolioEquitable Investment Management Group, LLC11,500$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Tiff Multi-Asset FundTIFF Advisory Services, LLC9,793$0 M<0.01%<0.01%+57%Jun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC12,174$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC12,106$0 M<0.01%<0.01%+28%Jul 31, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC9,500$0 M<0.01%<0.01%−34%Jun 30, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management8,245$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC8,247$0 M<0.01%0.01%−28%Jun 30, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.7,608$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC8,094$0 M<0.01%0.02%newJun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC7,224$0 M<0.01%0.01%+18%Jun 30, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC7,077$0 M<0.01%<0.01%+11%Jun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC6,990$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC7,754$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS7,650$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc.5,280$0 M<0.01%<0.01%−9.4%Jun 30, 2026
🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC6,257$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC4,633$0 M<0.01%<0.01%+18%May 31, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC4,715$0 M<0.01%0.01%−42%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Editas Medicine, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$177 K
16 sales, 3 insiders
Net, 12 months
-$177 K
open market only
Insiders on file
36
since
$254 K-$925 K$0Nov 2023: bought $0 (0 trades), sold $7 K (2 trades)Nov 23Dec 2023: bought $0 (0 trades), sold $1 K (1 trades)Mar 2024: bought $0 (0 trades), sold $925 K (2 trades)May 2024: bought $254 K (1 trades), sold $125 K (1 trades)MayJun 2024: bought $0 (0 trades), sold $70 K (2 trades)Jul 2024: bought $0 (0 trades), sold $99 K (2 trades)Sep 2024: bought $0 (0 trades), sold $7 K (2 trades)SepDec 2024: bought $0 (0 trades), sold $4 K (2 trades)Mar 2025: bought $0 (0 trades), sold $40 K (3 trades)Jun 2025: bought $0 (0 trades), sold $28 K (3 trades)JunJul 2025: bought $0 (0 trades), sold $13 K (1 trades)Aug 2025: bought $0 (0 trades), sold $2 K (1 trades)Sep 2025: bought $0 (0 trades), sold $18 K (3 trades)SepDec 2025: bought $0 (0 trades), sold $15 K (3 trades)Mar 2026: bought $0 (0 trades), sold $13 K (3 trades)Jun 2026: bought $0 (0 trades), sold $45 K (3 trades)JunJul 2026: bought $0 (0 trades), sold $13 K (1 trades)Aug 2026: bought $0 (0 trades), sold $2 K (1 trades)Sep 2026: bought $0 (0 trades), sold $19 K (3 trades)SepNov 2026: bought $0 (0 trades), sold $70 K (2 trades)
Bought (open market)Sold (open market)Hover a month for the totals
Editas Medicine, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Linda BurklyEVP, CHIEF SCIENTIFIC OFFICERSell10b5-1 plan-7,814$2.416$19 K70,379Form 4
filed Gilmore Neil O'NeillCEO, DirectorSell10b5-1 plan-21,164$2.416$51 K265,592Form 4
filed Gilmore Neil O'NeillCEO, DirectorGrant or award+43,567——286,756Form 4
filed Linda BurklyEVP, CHIEF SCIENTIFIC OFFICERGrant or award+16,533——78,193Form 4
filed Linda BurklyEVP, CHIEF SCIENTIFIC OFFICERSell10b5-1 plan-709$3.040$2 K61,660Form 4
filed Gilmore Neil O'NeillCEO, DirectorSell10b5-1 plan-5,124$3.040$16 K243,189Form 4
filed Amy ParisonSVP, Chief Financial OfficerSell10b5-1 plan-453$3.040$1 K13,839Form 4
filed Amy ParisonSVP, Chief Financial OfficerSell10b5-1 plan-678$2.580$2 K14,292Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Editas Medicine, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
38.7 M
39.6% of shares · 17.6 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-2.6 reverse split

Trading halts

  • 2026-05-26 13:30 UTC, code LUDP, resumed 13:35 UTC

Fails to deliver

  • : 446 shares at $2.35
  • : 85 shares at $2.45
  • : 9,845 shares at $2.75
  • : 301 shares at $2.69
  • : 180 shares at $2.83

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Editas Medicine, Inc. scorecard#

Passes 7 of the 22 checks that could be worked out: strongest in growth (3 of 5), weakest in valuation (1 of 5). Fiscal year 2025; market cap of Oct 19, 2026.

  • Valuation1 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median13.3×Price to book 13.3× against Biotechnology's median of 2.9×.
    • ✓Price to sales below its peers' median7.3×Price to sales 7.3× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-45.7%Free cash flow is -45.7% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth3 of 5
    • ✓Revenue grew in the newest year25.4%Revenue up 25.4% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years27.1%27.1% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median27.1%27.1% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-1.80 vs -2.88Diluted EPS -1.80 in fiscal 2025 against -2.88 the year before (report's currency).
    • ✗Net income higher than five years earlier-$160 M-$160 M in fiscal 2025 against -$116 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability1 of 5
    • ✗Profitable in the newest year-$160 MNet income -$160 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-394.9%-394.9% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-198.1%-198.1% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-394.9%-394.9% in fiscal 2025 against -1146.4% in 2022.
  • Financial health2 of 6
    • ✓Short-term assets cover short-term liabilities3.5×Current ratio 3.54 at the end of fiscal 2025.
    • ✗Debt below equity2.0×Debt to equity 1.96 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $93 M at the end of fiscal 2025.
    • ✗Operating income covers interest five times-25.9×Operating income -25.9 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-12.71Z-score -12.71 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year7.8%Diluted shares up 7.8% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Editas Medicine, Inc.'s statements, beside the median of Biotechnology.

Editas Medicine, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-394.9%-60.5%
Net margin-395.0%-68.9%
Return on equity-198.1%-61.0%
Revenue growth, 3 years a year27.2%12.9%
Revenue growth25.4%15.8%
Debt to equity1.96×0.26×

1of 8on the Piotroski tests of financial strength

  • Net loss of $160 million, the 12th loss-making year in a row.
  • Free cash flow was negative: -$166 million.
  • The share count rose 7.8% in the year.
  • Operating income covers the interest bill only -25.9 times.

Editas Medicine, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Editas Medicine, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue4132782026912132146.1
Research and development9019917817514315897918357
General and administrative50727071766865555146
Operating expenses201283247246219226161146134103
Operating income−160−251−169−226−193−135−141−114−120−97
Interest expense and finance costs2.10r————————
Other non-operating income (expense)−0.114165.50.6197.23.8−0.40.0
Income tax00000—————
Net income including minority interests———−220−193−116−134−110−120−97
Net income attributable to shareholders−160−237−153−220−193−116−134−110−120−97
Earnings per share, basic-1.80-2.88-2.02-3.21-2.85-1.98-2.68-2.33-2.98-3.02
Earnings per share, diluted-1.80-2.88-2.02-3.21-2.85r-1.98-2.68-2.33-2.98-3.02
Shares, weighted average (basic)89827669685950———
Shares, weighted average (diluted)89827669685950474032
Balance sheet
Cash and cash equivalents147132124142r204140238135147185
Short-term investments0138199203296262219234183—
Receivables1516105.10.36.00.40.00.70.1
Other current assets2.13.17.57.37.2116.35.82.41.8
Current assets164289341357507419464375332187
Property, plant and equipment3.5141216171411403940
Right-of-use (leased) assets16333444262529———
Total assets187342499514677573509420373229
Accounts payable2.65.58.39.55.16.45.85.34.04.6
Debt due within a year5.05.00———————
Current liabilities46776360475860363733
Long-term debt54520———————
Lease liabilities (non-current)12202433161923———
Total liabilities15920715015412417924618416595
Retained earnings−1,629−1,468−1,231−1,078−858−665−549−416−306−186
Shareholders' equity27134349361554394262236208135
Total liabilities and equity187342499514677573509420373229
Shares outstanding98838269686354494536
Cash-flow statement
Share-based compensation10212029432327272317
Cash from operating activities−165−210−132−177−164−180−41−46−9.4−50r
Capital expenditure−0.6−8.8−4.7−4.1−8.0−7.2−6.2−4.8−2.1−3.5
Cash from investing activities139162−3.7114−54−14112−53−184−3.5r
Debt issued—57————————
Debt repaid−2.90————————
Shares issued43011702492041167715497
Cash from financing activities40561181.32822241328715597
Change in cash147.9−18−6264−96103−12−3943r
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Editas Medicine, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Business segments

  • Reportable$41 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Editas Medicine, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$2.4 M
Gilmore Neil O'Neill
Other top executives, average
$999 K
the CEO earned 2.4× this
$100 invested is now
$23
Editas Medicine, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Gilmore Neil O'Neill$2.4 M$3.1 M$999 K$23
2024Gilmore Neil O'Neill$5.1 M−$3.1 M$1.3 M$14
2023Gilmore Neil O'Neill$2.4 M$3.8 M$1.6 M$114

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Editas Medicine, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling

Auditor changed 1 · Restructuring 1 · Directors and officers 5 · Material agreement 1 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 11

Editas Medicine, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officersResults announced8-K
Shareholder vote8-K
Material agreement8-K
Results announced8-K
Auditor changed8-K
Results announced8-K
Results announced8-K
Results announced8-K
Directors and officersBylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
RestructuringDirectors and officers8-K
Bylaws or fiscal year changed8-K
Results announced8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Editas Medicine, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2015$120 MNo. 1$50 to $250 million43equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Editas Medicine, Inc.#

$60 K spent on lobbying the US Congress and federal agencies in 2020, most often on health issues and medicare/medicaid.

Lobbying, 2020
$60 K
#1,116 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2020
2026 so far
—
  • Health Issues2 reports
  • Medicare/Medicaid2 reports

Lobbying firms hired in 2020

The Nickles Group, LLC $60 K

Editas Medicine, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2020$60 K—2
2019$200 K—4
2018$180 K—4

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Editas Medicine”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at Editas Medicine, Inc.#

3 labor condition applications certified in fiscal 2026 for 3 positions, at a median wage of $117 K a year.

Certified, FY2026
3
#1,345 among companies on value.today
Worker positions
3
Median wage offered
$117 K
a year, full-time
Applications filed
3
Editas Medicine, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Associate Scientist, Delivery Technology [00109010]Molecular and Cellular Biologists1$95 K
Scientist I, Assay Development in vitro/in vivo PharmacologyMolecular and Cellular Biologists1$135 K
Senior Associate Scientist [00114286]Molecular and Cellular Biologists1$117 K

Where: Cambridge, MA 3

Editas Medicine, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202633$117 K3
FY202555$102 K5
FY20241717$111 K19
FY202355$110 K5
FY202288$78 K8
FY202199$108 K9
FY20201616$68 K16

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as EDITAS MEDICINE, INC.

Layoffs at Editas Medicine, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
180
2024–2024
Latest
180 people
2024-12-11
Editas Medicine, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2024···········180180
Editas Medicine, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
180 peopleRestructuring planSEC 8-K“In connection with the Discontinuation, the Board approved a reduction in the Company’s employee workforce by approximately 180 positions, or approximately 65% (the “Reduction”).”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Editas Medicine, Inc. compares in Biotechnology

  • Market cap$363 M · higher than 54% of 726
  • Revenue$41 M · higher than 57% of 647
  • Net margin-144.9% · higher than 35% of 408
  • Revenue growth25.4% · higher than 65% of 438
  • Price / sales7.3× · lower than 53% of 339
  • Price / book13.3× · lower than 12% of 534
  • FCF yield-45.7% · higher than 26% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Editas Medicine, Inc.🇺🇸$363 M—-144.9%+25.4%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 19, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on 2021
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, Wikipedia, Wikidata, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Editas Medicine, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Editas Medicine, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Editas Medicine, Inc.? Suggest a correction